Nonlinear pharmacokinetics of cyclophosphamide and 4- hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation

Drug Metabolism and Disposition

Volumn 25, Issue 5, 1997, Pages 544-551

  Chen, Tian Ling ^a   Kennedy, M John ^b   Anderson, Lawrence W ^b   Kiraly, Susan B ^b   Black, Kraig C ^b   Colvin, O Michael ^b   Grochow, Louise B ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ALDOPHOSPHAMIDE; CYCLOPHOSPHAMIDE;

ADULT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; COMPUTER SIMULATION; DOSE RESPONSE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; FEMALE; GAS CHROMATOGRAPHY; HUMAN; KIDNEY CLEARANCE; MAJOR CLINICAL STUDY; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; NONLINEAR DYNAMICS; PHOSPHORAMIDE MUSTARDS; THIOTEPA;

ANIMALIA;

EID: 0030916085     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. M. Colvin and B. A. Chabner: Alkylating Agents. In "Cancer Chemotherapy" (B.A. Chabner and J.M. Collins, eds.), pp. 276-313. J. B. Lippincott Company, Philadelphia, 1990.
2. J. Hilton: Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and resistant L1210 cells. Biochem. Pharmacol. 33, 1867-1872 (1984).
3. N. E. Sladek: Metabolism and pharmacokinetic behavior of cyclophosphamide and related oxazaphosphorines. In "Anticancer Drugs Reactive Metabolism and Drug Interactions" (G. Powis, ed.), pp. 79-156. Pergamon Press, Tarrytown, NY, 1994.
4. O. M. Colvin: Mechanisms of resistance to alkylating agents. In "Anticancer Drug Resistance: Advances in Molecular and Clinical Research" (L. J. Goldstein and R. F. Ozols, eds.), pp. 249-262. Kluwer Academic Publishers, Norwell, MA, 1994.
5. J. E. Russo, J. Hilton, and O. M. Colvin: The role of aldehyde dehydrogenase liozymes in cellular resistance to the alkylating agent cyclophosphamide. In "Enzymology and Molecular Biology of Carbonyl Metabolism 2" (H. Weiner and T. G. Flynn, eds.), pp. 65-79. Alan R. Liss, Inc., New York, 1989.
6. M. B. Kastan, E. Schlaffer, J. E. Russo, O. M. Colvin, C. I. Civin, and J. Hilton: Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor Cells. Blood 75, 1947-1950 (1990).
7. T-L. Chen, J. L. Passos-Coelho, D. A. Noe, M. J. Kennedy, K. C. Black, O. M. Colvin, and L. B. Grochow: Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res. 55, 810-816 (1995).
8. N. E. Sladek, J. F. Powers, and G. M. Grage: Half-life of oxaphosphorines in biological fluids. Drug Metab. Dispos. 12, 553-559 (1984).
9. K. K. Chan, P. S. Hong, K. Tutsch, and D. L. Trump: Clinical pharmacokinetics of cyclophosphamide and metabolites with and without SR-2508. Cancer Res. 54, 6421-6429 (1994).
10. S. M. Yule, A. V. Boddy, M. Cole, L. Price, R. Wyllie, M. J. Tasso, A. D. J. Pearson, and J. R. Idle: Cyclophosphamide metabolism in children. Cancer Res. 5, 803-809 (1995).
11. J. T. Slattery, T. F., Kalhorn, G. B. McDonald, K. Lambert, C. D., Buckner, W. I. Bensinger, C. Anasetti, F. R. Appelbaum: Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J. Clin. Oncol. 5, 1484-1494 (1996).
12. L. W. Anderson, S. M. Luderman, O. M. Colvin, L. B. Grochow, J. M. Strong: Quatitation of 4-hydroxycyclophosphamide/aldophosphamide in whole blood. J. Chromatog. B. 667, 247-257 (1995).
13. L. W. Anderson, T.-L. Chen, O. M. Colvin, L. B. Grochow, J. M. Collins, M. J. Kennedy, J. M. Strong: Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin. Cancer Res. 2, 1481-1487, (1996).
14. D. W. Cockroft and M. H. Gault. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31-41 (1976).
15. M. J. Kennedy, D. K. Armstrong, A. M. Huelskamp, K. Ohly, B. V. Clarke, O. M. Colvin, L. B. Grochow, T.-L. Chen, and N. E. Davidson: Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J. Clin. Oncol. 13, 1136-1143 (1995).
16. M. Gibaldi and D. Perrier: Pharmacokinetics, 2nd Ed, pp. 1-43, 271-318, Marcel Dekker, Inc., New York, 1982.
17. W. L. Chiou: Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J. Pharmacokinet. Biopharm. 6, 539-546 (1978).
18. N. E. Sladek, D. Doeden, J. F. Powers, and W. Krivit: Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep. 68, 1247-1254 (1984).
19. L. B. Grochow and M. Colvin: Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 4, 380-394 (1980).
20. M. J. Moore, R. W. Hardy, J. J. Thiessen, S. J. Soldin, and C. Erlichman: Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin. Pharmacol. Ther. 44, 622-628 (1988).
21. R. J. Motzer, S. C. Gulati, W. P. Tong, C. Menendez-Botet, P. Lyn, M. Mazumdar, V. Vlamis, S. Lin, and G. Bosi: Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologoas bone marrow transplation in patients with refractory germ cell tumors. Cancer Res. 53, 3730-3735 (1993).
22. C. M. Bagley, Jr., F. W. Botick, and V. T. DeVita, Jr.. Clinical pharmacology of cyclophosphamide. Cancer Res. 33, 226-233 (1973).
23. M. I. Graham, I. C. Shaw, R. L. Souhami, B. Sidau, P.G. Harper, and A. E. M. McLean: Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother. Pharmacol. 10, 192-193 (1983).
24. N. E. Sladek, J. Priest, D. Doeden, C. J. Mirocha, S. Pathre, and W. Krivit: Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat. Rep. 64, 1061-1066 (1980).
25. M. D'Inacalci, G. Bolis, T. Facchinetti, M. Costantino, L. Morasca, P. Morazzoni, and M. Salmona: Decreased half life of cyclophosphamide in patients under continual treatment. Eur. J. Cancer 15, 7-10 (1979).
26. P.S. Hong, A. Srigritsanapol, and K.K. Chan. Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat. Drug Metab. Dispos. 19, 1-7, (1991).
27. L. J. Ayash, J. E Wright, O. Tretyakov, R. Gonin, A. Elias, C. Wheeler, J. P. Eder, A. Rosowsky, K. Antman, and E. Frei III: Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumor response. J. Clin. Oncol. 10, 995-1000 (1992).
28. E. D. Agura, M. C. Brown, R. Schaffer, G. Donaldson, and D. D. Shen: Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant. 16, 213-222 (1995).